Evidence map›Paper›PMID 40899881›Full record

ArticleJournal of clinical microbiology2025

Diagnostics and new treatment regimens for TB: can the Xpert MTB/XDR assay fill the gap for fluoroquinolone testing?

Derek T Armstrong, Emma C E Baird, Logan Pretty, Karen D'Agostino, Matthew Schwartz, Victoria L Campódonico, Nicole Parrish

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Derek T ArmstrongThe Johns Hopkins Medical Systems, Baltimore, Maryland, USA.ORCID 0000-0001-6223-4839
Emma C E BairdThe Johns Hopkins Medical Systems, Baltimore, Maryland, USA.
Logan PrettyThe Johns Hopkins Medical Systems, Baltimore, Maryland, USA.
Karen D'AgostinoThe Johns Hopkins Medical Systems, Baltimore, Maryland, USA.
Matthew SchwartzThe Johns Hopkins Medical Systems, Baltimore, Maryland, USA.
Victoria L CampódonicoThe Johns Hopkins Medical Systems, Baltimore, Maryland, USA.
Nicole ParrishThe Johns Hopkins Medical Systems, Baltimore, Maryland, USA.ORCID 0000-0002-4263-228X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapid diagnosis of resistance-conferring mutations to antibiotics used for the treatment of tuberculosis (TB) is critical for patient care and public health control efforts. Prior guidelines included the use of fluoroquinolones (FQs) for the treatment of drug-resistant TB, including multidrug-resistant TB, pre-extensively drug-resistant TB, and extensively drug-resistant TB. More recently, a short-course regimen for antibiotic-susceptible TB was introduced, which includes the use of a FQ, a drug class that diagnostic algorithms in the United States (US) typically do not test for if all first-line agents are susceptible. However, FQ mono-resistance has been documented by previous studies, and for this reason, we tested 319 archived

Indexed as

Antitubercular AgentsDrug Resistance, Multiple, BacterialFluoroquinolonesMolecular Diagnostic TechniquesMycobacterium tuberculosisTuberculosis, Multidrug-ResistantDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMutationUnited StatesAntitubercular AgentsFluoroquinolonesdiagnosticsdrug resistancemycobacteriatuberculosis

Identifiers

PMID40899881
PMCPMC12509795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.